Product Description
AZD-5055 is being developed by AstraZeneca for the treatment of Idiopathic Pulmonary Fibrosis. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05134727?term=AZD-5055&draw=2&rank=1)
Mechanisms of Action: PORCN Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers|Idiopathic Pulmonary Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| D8960C00001 | P1 |
Completed |
Idiopathic Pulmonary Fibrosis |
2023-03-31 |
23% |
2024-05-17 |
Patient Enrollment|Primary Endpoints|Treatments |
| D8960C00005 | P1 |
Completed |
Healthy Volunteers |
2023-12-04 |
69% |
2023-12-09 |
Primary Endpoints |
| D8960C00002 | P1 |
Completed |
Healthy Volunteers |
2023-02-09 |
69% |
2024-03-05 |
Patient Enrollment|Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/23/2023 |
News Article |
Redx and Jounce Announce Recommended Business Combination |